N-((3R,5R)-1-azabicyclo[3.2.1]oct-3-yl)-thieno[3,2-c]pyridine-6-carboxamide | 508203-63-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: N-((3R,5R)-1-azabicyclo[3.2.1]oct-3-yl)-thieno[3,2-c]pyridine-6-carboxamide
• 英文别名: N-[(3R,5R)-1-azabicyclo[3.2.1]octan-3-yl]thieno[3,2-c]pyridine-6-carboxamide
• CAS: 508203-63-2
• 化学式: C₁₅H₁₇N₃OS
• 分子量: 287.385
• InChiKey: RSYULNOZIQJAEW-ZYHUDNBSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  73.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-((3R,5R)-1-azabicyclo[3.2.1]oct-3-yl)-thieno[3,2-c]pyridine-6-carboxamide 在 盐酸 作用下， 以 甲醇 为溶剂， 生成
  参考文献：
  名称：

  Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the α7 nicotinic acetylcholine receptor: In vitro and in vivo activity

  摘要：

  A novel alpha 7 nAChR agonist, N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide ( 3a, PHA-709829), has been identified for the potential treatment of cognitive deficits in schizophrenia. The compound shows potent and selective a7 in vitro activity, excellent brain penetration, good rat oral bioavailability and robust in vivo efficacy in a rat auditory sensory gating model. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.04.070
• 作为产物：
  描述：

  thieno[3,2-c]pyridine-6-carboxylic acid 以58%的产率得到N-((3R,5R)-1-azabicyclo[3.2.1]oct-3-yl)-thieno[3,2-c]pyridine-6-carboxamide
  参考文献：
  名称：

  Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease

  摘要：

  该发明提供了Formula I中的化合物：1其中Azabicyclo为23这些化合物可以是药用盐或组合物的形式，或者是它们的外消旋混合物或纯对映体。Formula I中的化合物在已知涉及α7的药物中是有用的。

  公开号：

  US20030153595A1

文献信息

• Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds
  申请人：Corbett W. Jeffrey

  公开号：US20050245504A1

  公开（公告）日：2005-11-03

  The present invention relates to compositions and methods to treat diseases or condition with an α7 nAChR full agonist and an inhibitor of cholinesterase, and or beta secretase and or gamma secretase.

  本发明涉及利用α7 nAChR全激动剂和胆碱酯酶抑制剂，和/或beta秘鲁和/或gamma秘鲁的组合物和方法来治疗疾病或症状。
• Treatment of attention defecit hyperactivity disorder
  申请人：Rogers N. Bruce

  公开号：US20050107425A1

  公开（公告）日：2005-05-19

  The present invention relates to compositions and methods to treat ADHD with an α7 nAChR full agonist and psychostimulants and/or monoamine reuptake inhibitors.

  本发明涉及使用α7 nAChR全激动剂和精神刺激剂和/或单胺再摄取抑制剂的组合物和方法来治疗ADHD。
• Treatment of diseases with alpha-7nACh receptor full agonists
  申请人：Groppi E. Vincent

  公开号：US20060019984A1

  公开（公告）日：2006-01-26

  The present invention relates to compositions and methods to treat diseases or conditions with alpha-7 nicotinic acetylcholine receptor (AChR) full agonists by decreasing levels of tumor necrosis factor-alpha and/or by stimulating vascular angiogenesis.

  本发明涉及使用α-7烟碱乙酰胆碱受体（AChR）全激动剂治疗疾病或病症的组合物和方法，通过降低肿瘤坏死因子-α的水平和/或刺激血管生成来实现。
• Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease
  申请人：Walker Patrick Daniel

  公开号：US20050234092A1

  公开（公告）日：2005-10-20

  The invention provides compounds of Formula I: wherein Azabicyclo is These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which α7 is known to be involved.

  本发明提供了I式化合物：其中Azabicyclo为这些化合物可以是药物盐或组合物，外消旋混合物或其纯对映体。式I的化合物在已知α7参与的制药领域中是有用的。
• Therapeutic combination for cognititon enhancement and psychotic disorders
  申请人：Romano Joseph Steve

  公开号：US20050215571A1

  公开（公告）日：2005-09-29

  This invention relates to combinations of an atypical antipsychotic, and a nicotinic receptor agonist or antagonist, kits containing such combinations, pharmaceutical compositions comprising such combinations, and methods of using such combinations to treat patients suffering from cognitive impairment disorders or psychotic disorders or conditions.

  本发明涉及一种非典型抗精神病药和一种烟碱受体激动剂或拮抗剂的组合物、含有这种组合物的试剂盒、包含这种组合物的药物组合物以及使用这种组合物治疗患有认知障碍疾病或精神病的患者的方法。